Establishing a whole blood CD4+ T cell immunity measurement to predict response to anti-PD-1 - Yamaguchi, Ou; Atarashi, Kazuyuki; Yoshimura, Kenichi; Shiono, Ayako; Mouri, Atsuhito; Nishihara, Fuyumi; Miura, Yu; Hashimoto, Kosuke; Miyamoto, Yoshiaki; Uga, Hitoshi; Seki, Nobuo; Matsushima, Tomoko; et al. (BMC cancer, 2022)
Keywords: Analysis; Apoptosis; B7-H1 Antigen - metabolism; Biological markers; Biomarkers; Biopsy; Blood; Cancer; Cancer immunotherapy; Carcinoma, Non-Small-Cell Lung - metabolism; Care and treatment; CD25 antigen; CD4 antigen; Chemotherapy; Diagnosis; Dosage and administration; Effector CD4+ T cells; Effector cells; Flow cytometry; Foxp3 protein; Heparin; Humans; Immune checkpoint inhibitors; Immunoregulation; Immunotherapy; Informed consent; Leukocytes, Mononuclear - metabolism; Lung cancer; Lung cancer, Non-small cell; Lung Neoplasms - metabolism; Lymphocytes; Lymphocytes T; Medical examination; Monoclonal antibodies; Nitrogen; Nivolumab - pharmacology; Nivolumab - therapeutic use; Non-small cell lung cancer; Non-small cell lung carcinoma; Patient outcomes; Patients; PD-1 blockade therapy; PD-1 protein; Pembrolizumab; Peripheral blood mononuclear cells; Programmed Cell Death 1 Receptor - metabolism; Receptor antibodies; Small cell lung carcinoma; Software; T-Lymphocytes, Regulatory - metabolism; Tumors; Japan; United States--US; Biomarkers; Flow cytometry; PD-1 blockade therapy; Effector CD4+ T cells; Non-small cell lung cancer